The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully ...

New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...

Actor Eric Dane, who recently announced his ALS diagnosis, will guest star as a patient with the disease on the TV drama ...

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...

The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research ---- The Hoffman ALS Clinical Trial Awards ...

Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery. When Columbia neurologist and ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

BREMERTON, WA / ACCESS Newswire / July 7, 2025 / On July 4, 1939, Lou Gehrig delivered his iconic “luckiest man” speech, announcing his retirement from the New York Yankees. On that day, ALS ended his ...

Eric Dane returns to television with a guest appearance on Brilliant Minds, portraying an ALS patient in a special episode. Here’s a look at his role, the storyline, and how the show integrates his ...